Celon Pharma S.A. (WSE:CLN)

Poland flag Poland · Delayed Price · Currency is PLN
22.30
+0.50 (2.29%)
Jun 5, 2025, 5:00 PM CET
42.95%
Market Cap 1.20B
Revenue (ttm) 215.11M
Net Income (ttm) -43.86M
Shares Out 53.86M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE 23.41
Dividend 0.08 (0.36%)
Ex-Dividend Date Jun 27, 2024
Volume 20,538
Average Volume 26,683
Open 21.70
Previous Close 21.80
Day's Range 21.65 - 22.50
52-Week Range 15.14 - 32.90
Beta 0.83
RSI 39.08
Earnings Date May 21, 2025

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o. [Read more]

Sector Healthcare
Founded 2002
Employees 558
Stock Exchange Warsaw Stock Exchange
Ticker Symbol CLN
Full Company Profile

Financial Performance

In 2024, Celon Pharma's revenue was 204.98 million, a decrease of -4.18% compared to the previous year's 213.92 million. Losses were -34.45 million, 22.5% more than in 2023.

Financial Statements

News

Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease

Statistically significant improvement in primary endpoint (UDysRS total scale) at Week 4 and positive benefit in the key secondary endpoint (UDysRS objective subscale), beginning at Day 7 Favorable to...

3 months ago - Benzinga